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Relationship between somatic 
mosaicism of Pax6 mutation 
and variable developmental eye 
abnormalities—an analysis of 
CRISPR genome-edited mouse 
embryos
Akihiro Yasue1, Hitomi Kono2, Munenori Habuta2, Tetsuya Bando2, Keita Sato2, Junji Inoue2, 
Seiichi Oyadomari3, Sumihare Noji4, Eiji Tanaka  1 & Hideyo Ohuchi2
The clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 
(Cas) system is a rapid gene-targeting technology that does not require embryonic stem cells. To 
demonstrate dosage effects of the Pax6 gene on eye formation, we generated Pax6-deficient mice 
with the CRISPR/Cas system. Eyes of founder embryos at embryonic day (E) 16.5 were examined and 
categorized according to macroscopic phenotype as class 1 (small eye with distinct pigmentation), class 
2 (pigmentation without eye globes), or class 3 (no pigmentation and no eyes). Histologically, class 1 
eyes were abnormally small in size with lens still attached to the cornea at E16.5. Class 2 eyes had no 
lens and distorted convoluted retinas. Class 3 eyes had only rudimentary optic vesicle-like tissues or 
histological anophthalmia. Genotyping of neck tissue cells from the founder embryos revealed somatic 
mosaicism and allelic complexity for Pax6. Relationships between eye phenotype and genotype were 
developed. The present results demonstrated that development of the lens from the surface ectoderm 
requires a higher gene dose of Pax6 than development of the retina from the optic vesicle. We further 
anticipate that mice with somatic mosaicism in a targeted gene generated by CRISPR/Cas-mediated 
genome editing will give some insights for understanding the complexity in human congenital diseases 
that occur in mosaic form.
Pax6 is a homeodomain-containing transcription factor that is critical for eye and nasal development in most 
animals, including Drosophila, mice, and humans, as well as in the neural development and differentiation of pan-
creatic endocrine cells1–3. It has been shown that the effects of Pax6 mutation depend on extent of mutation and 
gene dosage. That is, large deletion mutation produces a more severe phenotype than hypomorphic mutations 
such as missense substitution of an invariant amino acid, and homozygous mutants are more severely affected 
than heterozygous mutants, which exhibit haploinsufficiency. For example, homozygous Pax6-null mutation in 
mice results in a failure to develop eyes and nasal cavities and embryonic lethality; meanwhile heterozygous Pax6 
mutation in humans results in small eyes and aniridia4–6.
The CRISPR/Cas system of RNA-guided genome editing is used as a facile and rapid gene targeting tech-
nique for altering genes in a wide variety of cell types, beyond embryonic stem cells, and in various organisms 
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including mice7, 8. Cas9 nuclease, which is guided by single guide RNA (sgRNA), hybridizes specifically with 
and induces double-stranded breaks (DSBs) in complementary genomic sequences. The DSBs are repaired by 
either non-homologous end-joining (NHEJ) or homology-directed repair in the presence of donor DNA. Because 
NHEJ leads to small insertions and deletions, the open reading frame is disrupted, thereby inactivating the target 
gene.
Previously, we used the CRISPR/Cas system to generate Fgf10-knockout mice and obtained limbless mice, 
identical to those produced by conventional gene targeting techniques9, 10. In the genome-edited founder mice, 
varying degrees of mosaicism in mutations of targeted genes have been reported11–13. Here, we used the CRISPR/
Cas system to generate Pax6-deficient mice. We focused on eye phenotype and examined relationship between 
genotype and phenotype of Pax6-mutated mice. We studied the effects of Pax6 gene dosage on eye development 
by utilizing observation of Pax6-mosaic founder mice.
Results
CRISPR/Cas-mediated gene knockout. We designed target sites in mouse Pax6 in exon 5 [target 1 (T1)] 
or exon 6 [target 2 (T2)], each of which encodes part of the paired domain (PD), as shown in Fig. 1. The PD was 
chosen for targeting because a considerable number of mouse Pax6 mutants and human aniridia cases had muta-
tions in the PD14–16. Furthermore, target sites were easily determined with respect to the proto-spacer adaptor 
motif (PAM; NGG nucleotides) sequence. T1 is located in the exon-intron boundary, whereas T2 is within exon 
6. We microinjected T1 or T2 sgRNA and Cas9 mRNA into the cytoplasm of fertilized mouse eggs at the one-cell 
stage. After being cultured overnight, the injected zygotes were transferred into the oviducts of pseudo-pregnant 
females.
Pax6-CRISPR founder mice exhibited varying degrees of eye defects. First, to know the gene 
knockout efficiency achieved by the CRISPR/Cas system, we examined the eye phenotypes of founder embryos 
at E16.5 under a dissecting microscope. The semidominant and homozygous lethal “Small eye” (Sey/Sey) muta-
tion (a null mutation in Pax6) is known to cause failure of lens development from the head surface ectoderm, 
thereby aborting eye morphogenesis3, 4. Therefore, we anticipated that it would be easy to evaluate the efficiency 
of CRISPR/Cas system by observing the external morphology of founder embryonic eyes.
We observed embryonic eyes under a stereomicroscope and found varying degrees of eye malformation 
(Figs 2 and S1). We categorized the eyes into three phenotypes: class 1, small eye with distinct pigmentation 
(Fig. 2b; compare with Fig. 2a); class 2, pigmentation without obvious eye globes (Fig. 2c); and class 3, no pigmen-
tation and no eyes (Fig. 2d). T1 embryos (N = 22) exhibited class 1 (48%, N = 12, 21 eyes), class 2 (32%, N = 10, 14 
eyes), and class 3 (20%, N = 6, 9 eyes) phenotypes. Meanwhile, T2 embryos (N = 19) exhibited only class 2 (5%, 
N = 1, 2 eyes) and class 3 (95%, N = 18, 36 eyes) phenotypes (for details, see Table 1). Although larger numbers 
of severe eye phenotypes were observed in T2 than in T1 embryos, the samples are not large enough to support 
strong conclusions. Nonetheless, given this early pattern of phenotypes, it might be targeting within an exon, as 
in T2, disrupts genes more efficiently than altering an intron (Fig. 1). However, in vitro analysis of cleavage effi-
ciency by Cas9 nuclease under the T1 or T2 sgRNA showed no obvious difference between these two target sites 
(Fig. S2). On the other hand, there were some embryos exhibiting size and morphological differences between 
right and left eyes; for example, T1#9 and T1#10 embryos have class 3 eyes on the right side and class 2 eyes on 
the left side (Fig. S3, Tables S1 and S2).
Correlation between external eye morphology and histology. To substantiate the stereoscopic eye 
phenotype, hematoxylin-eosin (HE)-stained coronal sections were examined histologically (28 eyes; N = 9 for 
T1, N = 5 for T2; Table 2). Representative results are shown in Figs 3 and S4. In both eyes of the normal embry-
onic day (E) 16.5 embryo, a lens and neural retina (NR) had formed with an optic nerve, retinal pigmented 
epithelium (RPE), and iris (Figs 2e and S4a,b). In the class 1 T1#4 embryo, both eyes were small and the lenses 
remained attached to the corneas (Figs 3a,b and S4c,d), which is characteristic to the Pax6-heterozygous eye17, 18. 
Furthermore, the right eye had a convoluted NR (Fig. 3a). In the class 1 T1#18 embryo, the right eye had a smaller 
lens and several separated NR-folds (Fig. 3c). In the class 2 T1#2 and T2#10 embryos, the eyes had no lenses and 
the retinas were distorted with multiple convolutions (Fig. 3e–h), a phenotype resembling that in embryos in 
which Pax6 was specifically inactivated in the eye surface ectoderm19. The putative RPE cells were discernible, but 
Figure 1. Mouse Pax6 gene structure and single guide sgRNA design. Diagram of mouse Pax6 locus with 16 
exons. The red boxes show exons that give rise to the PD. The blue boxes show other exons. Sequences in exon 
5 and exon 6 were targeted to generate two sgRNAs (T1 and T2, in red). PAM sequences are indicated in blue. 
Uppercase letters indicate coding sequence, and lowercase letters indicate intron sequence.
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appeared mostly with hypopigmentation and with columnar rather than mature cuboidal shaped cells (Fig. 3e,f). 
The putative iris cells appeared as patches of cells with pigmentation near the presumptive cornea (Fig. 3g,h). In 
class 3 embryos, there were no lenses whatsoever. For example, in the T1#7 embryo, vestigial optic vesicle-like 
epithelial tissues with pigmentation were observed (Fig. 3i,j). In the T2#1 embryo, which exhibited histological 
anophthalmia, there were no apparent optic vesicle-like tissues (Fig. 3k,l). In the T2#13 embryo, there were only 
vestigial optic vesicle-like epithelial tissues, but a complete absence of pigmented cells (Fig. 3m,n). Thus, the class 
3 phenotype resembled the Pax6-null mouse phenotype20.
The histologically observed abnormalities are summarized in Table 2. Only one (T1#6) out of 14 embryos 
(7%) examined had histologically normal eye structures on both sides; the rest had defects of some sort in at least 
one eye. However, even in T1#6’s eyes, retinal development appeared to be delayed (Fig. 4l,q; described later). Our 
histological observations support the notion that classification of Pax6-CRISPR eye phenotypes based on external 
morphology corresponds with the extent of histological abnormality fairly well.
Genomic analysis of Pax6-CRISPR founder mice. To elucidate phenotype-genotype associations, we 
analyzed the genomic sequences of Pax6-targeted regions amplified by PCR. We analyzed genomic DNA samples 
from 20 founder embryos, including 15 of E16.5 embryos and 5 of E11.5 embryos: Each genomic PCR product 
was ligated to a plasmid DNA, the ligation products were transformed, and a set of resultant clones (22–89) was 
sequenced (Figs S5 and S6). We found targeted mutations (i.e. deletions and insertions) in the T1 or T2 regions 
along with wild-type sequences. For example, in T1#2, seven different mutations were found, including dele-
tion of 12 nucleotides that likely abolished a splice donor site, resulting in a truncated gene product. 66.7% of 
sequenced clones showed the Pax6 mutations resulting in the truncated proteins (Fig. S5 and Table S3). In T1#7, 
we observed a two-amino acid (Arg44-Ile45) deletion (42.6%), which, based on a human PAX6 mutation data-
base16, would be expected to result in translation of a Pax6 protein with reduced DNA-binding activity. Some of 
Figure 2. Eye phenotypes of Pax6-CRISPR founder mice at E16.5. (a–d) Lateral view of the eye on the right 
side. (a) Wild-type eye. Based on stereomicroscopic observations, we categorized the eyes into three phenotype 
classes: class 1 (b) class 2 (c) and class 3 (d). (e) HE-stained coronal sections of wild-type eye. The retina has 
differentiated to form the inner neuroblastic layer. ir, iris; le, lens; nr, neural retina; on, optic nerve; rpe, retinal 
pigmented epithelium. Scale bars: 100 μm.
Phenotype
T1 
(N = 22 : T1#1 ~ #22)
T2 
(N = 19 : T2#1 ~ #19)
Right eye Left eye Right eye Left eye
Class 1 11 10 0 0
Class 2 5 9 1 1
Class 3 6 3 18 18
Table 1. Number of Pax6-CRISPR/Cas embryos examined by stereoscopy.
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the founder embryos had frame-shift mutations resulting in the truncated proteins due to premature stop codons. 
For example, T1#18 carried three types of frame-shift mutations (30.6%) and one type in-frame mutation (40.8%) 
(Fig. S5 and Table S3). The in-frame mutation in T1#18 caused a three-amino acid (Arg-Ile-Leu) deletion in the 
PD. Although we did not determine the effects of particular types of Pax6 mutations on specific eye phenotypes, 
we compared percentages of mutated sequences that result in C-terminal truncated Pax6 proteins (null function), 
in-frame mutations (null or reduced function), and wild-type sequences in each embryo histologically examined 
(Fig. 3o). We found that in class 3, the most severe eye phenotype, that histologically resembles those caused 
by null mutations, there is high incidence of truncated mutations and almost no wild-type Pax6 protein. These 
results suggest a correlation between the eye phenotype severity and the percent Pax6 mutations revealed by 
sequencing and further highlight somatic mosaicism and allele complexity of the Pax6 gene in founders gener-
ated by CRISPR/Cas-mediated mutagenesis of zygotes.
Immunohistochemistry of Pax6 and βIII tubulin. To reveal the localization of residual Pax6-expressing 
cells in the Pax6-CRISPR founder embryos, we performed immunohistochemistry on coronal head sections with 
an anti-Pax6 antibody (Fig. 4a–e,k–o). Because we used an anti-Pax6 antibody raised against the C-terminus of 
the mouse Pax6 protein (see Materials and Methods), Pax6-immunoreactivity indicated wild-type (+/+) or het-
erozygous (+/−) Pax6-expressing cells, and potentially also Pax6-homozygous mutated cells in which in-frame 
insertions and deletions retained normal C-terminal amino acid structures.
In the normal developing eye, Pax6 is expressed in lens epithelial cells and retinal progenitor cells, and is 
expressed later in the anterior peripheral retina, retinal ganglion cell layer, and inner half of the inner nuclear 
layer20–22 (Fig. 4a,k). In the class 1 T1#6 eye, for example, which exhibited an overall normal structure, abundant 
Pax6 protein was present in the lens epithelium and in retinal progenitor cells of the NR (Fig. 4b,l). However, the 
NR was immature without a layered structure. In the class 2 T1#12 eye, the retina was distorted with multiple 
convolutions, possibly due to the hypoplastic lens (Fig. 4c)19. Pax6 protein was localized distinctly within the sep-
arated NR-folds (Fig. 4m). In the class 3 T1#11 embryo, a Pax6 protein was detected in the residual optic vesicle 
tissues (Fig. 4d,n). However, genomic analysis showed that the embryo had two types of Pax6 mutations: One 
encodes a C-terminal truncated Pax6 (57.9%) and the other a 3 amino acid insertion in the PD (42.1%) (Fig. 4u 
and Table S4). This means that the anti-Pax6 antibody detected the mutated protein that is functionally defective 
Class Lens Iris RPE NR
T1
#4
R 1 N N h h
L 1 N N N N
#6
R 1 N N N N
L 1 N N N N
#18
R 1 N N h h
L 1 N N N N
#2
R 2 a h h h
L 2 a N h h
#9 L 2 a h h h
#12
R 2 a h h h
L 2 N N h h
#13 L 2 a h h h
#7
R 3 a h h h
L 3 a h h h
#9 R 3 a h h h
#11
R 3 a h a h
L 3 a h h h
#13 R 3 a h h h
T2
#10
R 2 a h a h
L 2 a n a h
#1
R 3 a a a a
L 3 a a a a
#3
R 3 a a a h
L 3 a a a a
#8
R 3 a a a h
L 3 a h h h
#13
R 3 a a a h
L 3 a a a h
Table 2. Eye phenotypes of Pax6-CRISPR/Cas embryos examined histologically. T1, N = 9; T2, N = 5. The 
number after each # is identifies each embryo. R, right eye; L, left eye. N, normal structure; h, hypoplasia; 
a, agenesis. T1#6 eyes had normal histology, with delayed retinal development (see Fig. 4l,q) vs. wild-type 
(Fig. 4k,p).
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and virtually null as the eye phenotype exhibits nearly anophthalmia. On the other hand, in the T2#3 embryo, 
the level of immunoreactivity was quite low (Fig. 4e,o), in which the mosaicism of Pax6 mutations was found 
but all clones so far sequenced were mutated to encode C-terminal truncated proteins (Fig. 4u and Table S4). 
These observations suggest that residual Pax6-expressing cells (wild-type and/or Pax6-heterozygous) contribute 
to reduced or hyperproliferated retinal structures. However, these embryos obviously had not enough functional 
Pax6-expressing cells required for formation of wholly normal eye morphology.
We next performed immunohistochemistry for the neuron-specific marker βIII tubulin (Tuj1) to assess 
whether the NRs of Pax6-CRISPR founder embryos initiated neural differentiation (Fig. 4f–j,p–t). Normal E16.5 
retina displayed the characteristic pattern of neuronal cell differentiation, as indicated by Tuj1 immunoposi-
tivity in retinal ganglion cells, the first differentiating retinal cells23 (Fig. 4f,p). In class 1 T1#6 retina, a similar, 
but apparently developmentally earlier Tuj1 expression pattern was observed (Fig. 4g,q); that is, substantially 
Figure 3. HE-stained eye tissues from founder mice at E16.5. Coronal sections are shown. (a–d) Class 1 eyes. 
(e–h) Class 2 eyes. (i–n) Class 3 eyes. In panels (e–j) the red arrowhead shows the prospective RPE, the blue 
arrowhead shows pigmented epithelial cells of the iris or RPE, and the black arrowhead shows the prospective 
iris. (o) Percentage of mutated and wild-type genotypes found in each embryo. Mut-Tr, mutations encoding 
truncated Pax6 proteins; Mut-IF, in-frame mutations; Wt, wild-type. Detailed results are shown in Fig. S5 and 
Table S3. Scale bars: 100 μm.
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fewer Tuj1-positive retinal ganglion cells were observed than in wild-type retina (Fig. 4f,p). In class 2 T1#12 
eye tissue, the autonomous development of each retina fold was demonstrated by a normal appearing Tuj1 dis-
tribution within each of the NR folds (Fig. 4h,r). Localization of Tuj1 was observed even in the residual optic 
Figure 4. Pax6 and Tuj1 immunoreactivity. Localization of Pax6 (a–e,k–o), and βIII tubulin (f–j,p–t) proteins 
in wild-type (left 4 panels) and Pax6-CRISPR (rest of the panels) embryos at E16.5. High magnification images 
of eyes (boxed area in a–j) are shown in (k–t). Serial coronal sections were immunolabeled with anti-Pax6 
and anti-βIII tubulin (Tuj1) antibodies. (a,k) In the E16.5 normal retina, expression of Pax6 is downregulated 
and restricted to retinal ganglion cells of the inner neuroblastic layer and to the innermost cells of the outer 
neuroblastic layer. (b,g) Oblique section from the T1#6 embryo confirming that both eyes were categorized 
appropriately as class 1 phenotype. (f,p) In the E16.5 normal retina, βIII tubulin is intensely detected in the 
inner neuroblastic layer. (l,q) Retinal development has delayed and the retina is not layered yet. Pax6 protein 
is detected all over the retina (l). βIII tubulin is restricted to the innermost thin domain where differentiating 
retinal ganglion cells reside (q). (n) The anti-Pax6 antibody detects abnormal Pax6 protein in which 3 amino 
acids are inserted in the PD. (u) Percentage of mutated and wild-type genotypes found in each embryo. Mut-Tr, 
mutations encoding truncated Pax6 proteins; Mut-IF, in-frame mutations; Wt, wild-type. Detailed results are 
shown in Fig. S5 and Table S4. (v) Relationship between the percent Pax6-positive retinal area and the percent 
truncated Pax6 mutations. The percent Pax6-positive retinal area showed an apparent negative correlation 
with the percent truncated Pax6 mutations, but it was not statistically significant (rs = −0.620; P = 0.056). (w) 
Similarly, the estimated area (mm2) of Tuj1-positive retina was positively correlated with that of Pax6-positive 
retina (rs = 0.830; P = 0.003). Scale bars: 500 μm in (a–j) and 100 μm in (k–t).
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vesicle-like tissues of class 3 eyes (Fig. 4i,j,s,t), indicating that neuronal cell differentiation had at least started in 
the Pax6-CRISPR founder retina.
Previous studies using chimeras, trangenics, and analysis of Pax6-heterozygouts have shown that Pax6 
works in a highly dose-dependent manner. Regarding this, we sought to examine whether the incidence of 
Pax6-mutations relates to the amount of functional Pax6 protein. We measured the area of Pax6-positive 
domains on immunostained sections and that of the entire retina. A scatter plot was built between percentage of 
Pax6-positive area per retina and that of truncated Pax6 mutations (Fig. 4v). We found that a moderate negative 
correlation was observed between them, but it was not statistically significant (Fig. 4v). In contrast, a scatter plot 
between the Tuj1-positive area and that of Pax6-positive area showed a significant positive correlation between 
them (Fig. 4w). Thus, in this study, the area of Pax6-positive domains revealed by immunostaining almost reflects 
the presence of wild-type or C-terminal retained Pax6 proteins in Pax6-CRISPR founder retina. The positive 
correlation between the area of Pax6 and Tuj1 indicates that Pax6-gene dosage may have a positive effect on the 
expansion of Tuj1-posive cells, retinal ganglion cells.
Pax6-mosaic optic vesicle is composed of Pax6-positive/-negative cells. To understand how the 
mosaic pattern of the retinal cells segregate, we examined eye phenotypes of Pax6-CRISPR founder embryos at 
E11.5. In normal embryos, the optic cup and lens vesicle form by E11.5. In some Pax6-CRISPR founder embryos, 
the neuroepithelium of optic vesicles overproliferated and there was no development toward the optic cup nor 
lens development (class 2) (Fig. S7a–d,q–t). In other founder embryos, in addition to the lack of lens vesicles or 
placodes, development of optic vesicles ceased (class 3) (Fig. S7e–h,m–p). Histological sections were immunos-
tained with the anti-Pax6 antibody. We found that Pax6-positive cells and -negative cells were intermingled in 
the deteriorated optic vesicles (Fig. 5). In the T1#2 embryo (class 2), Pax6-postive cells were wild-type or hete-
rozygous cells, whereas Pax6-negative cells were those with truncated (null) Pax6 proteins (Figs 5a,b and S6, S7u, 
Table S7). In the T1#9 embryo (class 3), Pax6-postive cells were those with defective Pax6 proteins (3 amino acid 
deleted in the PD) and Pax6-negative cells were those with truncated (null) Pax6 proteins (Figs 5c,d and S6, S7u, 
Table S7). In both embryos, it appears that Pax6-positive cells and -negative cells were segregating: There were 
portions where Pax6-negative cells are grouped together in the optic vesicle (Figs 5b,d and S8). Thus, around 
E11.5 the mosaic pattern of the cells with different genotypes is segregating in the Pax6-mosaic mouse.
Discussion
In this study, morphological and genomic analyses demonstrated that our Pax6-CRISPR founder embryos with 
different Pax6 mutations had eye phenotypes of varying degrees of hypoplasticity (class 1 to 3). Although how 
particular types of Pax6 mutation determined yield specific phenotypes is not unknown in the present study, we 
sought to assign the mutants’ possible genotypes based on phenotype and affected genomic region sequence. 
Histology showed that the lenses in class 1 eyes (T1#4 and #18) had failed to detach from the cornea and the ret-
ina was folded. The Pax6-heterozygote (Sey/+) mouse has an abnormally small and vacuolated lens with folding 
of the optic cup margins24, and a diploid level of Pax6 is required for detachment of the lens vesicle from the sur-
face ectoderm17. Therefore, the genotypes of our class 1 embryos may be comparable to Pax6+/− heterozygosity 
or a mixture of wild-type (Pax6+/+) and bi-alleic Pax6 mutations (Pax6−/−). The retinal development of the 
class 3 eyes had terminated at the optic vesicle stage or exhibited histological anophthalmia, similar to eye tissues 
found in Pax6-null mutants20. Histology of class 2 eyes showed no or reduced lens formation but convoluted reti-
nas, which fits with a phenotype that is intermediate between class 1 and 3. This implies that intermediate level of 
Pax6 expression may lead to retinal overproliferation per se, not due to lens deficiency.
Founder generations of frogs with Pax6-targeted genome editing12, 25 have been described as having mosaic 
eye phenotypes similar to those observed in this study. A recent paper shows that using electroporation, Cas9 
protein with sgRNA, and early pronuclear zygotes is a most effective way to generate non-mosaic mutants in the 
mouse13. Our results indicated genetic mosaicism ranging from two to eight including wild-type (Tables S3, S4 
and S7). This could be interpreted as that before E0.8 the translational machinery is not completely activated in 
the zygotes13, and therefore Cas9 is not effective at the time of microinjection, but nuclease activity of Cas9 might 
drag on as cleavage proceed. Thus, balancing of the concentration of Cas9/sgRNA injected must be useful to reg-
ulate genetic mosaicism, which awaits a further study.
So far, detailed analyses of eye phenotypes and their correlations with genotypes in F0 animals validating 
the influence of Pax6 gene dosage on eye development have not been reported. Outcomes of altering Pax6 levels 
on eye development have been examined in studies of Pax6-heterozygous null mutants17, Pax6 chimeras26–28, 
mice with conditional inactivation of Pax619, and Pax6-overexpressing transgenic mice29. Additionally, series 
of Pax6-hypomorph alleles have been used in gene-dosage studies. For example, the Pax67Neu mutation, which 
is a base pair substitution in the Kozak sequence, results in a reduced level of Pax6 translation product14. In the 
resultant Pax6-hypomorph homozygous mutant, lenses do not develop, but rudimentary retinas do, as in the 
class 3 eyes in the present study (Fig. 3i,j). Taken together, analysis of our Pax6-mosaic founder mice leads to the 
conclusion that the surface ectoderm, which develops into the lens and cornea, is more sensitive to reduced levels 
of Pax6 than the optic vesicle, from which the retina and iris develop3, 30.
Although the importance of Pax6’s role in regulating proliferative rates depends on local expression of other 
regulatory factors, Pax6 is required invariably for proliferation of retinal progenitor cells and their multipotency3. 
Therefore, the rudimentary and immature retina with only initial differentiation (Tuj1 expression) observed in 
class 3 eyes may be explained by repression of proliferation due to Pax6 deficiency. Previous Pax6 chimera exper-
iments showed that Pax6−/− and Pax6+/− cells segregate to form an ectopic optic vesicle or lens vesicles and 
postulated that it is due to different adhesive properties of wild-type and mutant cells27. Although we did not 
detect ectopic optic or lens vesicles in E11.5 Pax6-CRISPR founder embryos, segregation between the cells with 
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different Pax6-genotypes also occurred in the abnormal optic vesicles, which supports the notion that Pax6 reg-
ulates a number of cell surface and adhesion molecules31.
Congenital aniridia (OMIM 106210) is a panocular disorder characterized by iris hypoplasia and reduced 
visual acuity16, 32. Classical isolated aniridia is a haploinsufficiency disorder caused by mutations in the Pax6 gene. 
This anomaly is inherited with high penetrance, albeit with variable expressivity, and approximately a third of 
congenital aniridia cases are sporadic with no family history33. Variable expressivity of Pax6 mutations has been 
explained by mosaicism, mutation type (chromosomal abnormality, nonsense mutation, missense mutation, etc.) 
and other factors apart from the Pax6 mutation itself15, 34. Somatic mosaicism has been observed in other genetic 
diseases, such as retinitis pigmentosa and retinoblastoma, as well35. Many endogenous factors (e.g., mobile ele-
ments, DSBs in DNA, unbalanced chromosomal segregation) and some exogenous factors (e.g., nicotine and UV 
exposure) can generate somatic mutations, thereby causing somatic mosaicism36. Genome editing may be used 
to produce a mosaic mixture of mutant and wild-type cells in tissues. Thus, we envision that making and study-
ing CRISPR/Cas-mediated mosaic mice with particular mutations of interest will help to elucidate why human 
congenital diseases exhibit variable expressivity and to reveal how somatic mosaicism caused by genetic and/or 
environmental factors is involved in human developmental abnormalities.
Methods
Animals. All animal care and experiments were carried out in accordance with the Guideline for Animal 
Experiments of Tokushima University and were approved by the Ethics Committee of Tokushima University for 
Animal Research (approval numbers 10110 and T27-16).
Figure 5. Pax6 immunoreactivity in the mosaic optic vesicle at E11.5. (a,b) Representative transverse sections 
of embryonic heads from T1#2_e11 and T1#9_e11, respectively. Green indicates localization of Pax6 protein 
and nuclei are stained with DAPI (blue). The arrow in (a,c) indicates the retinal neuroepithelium enlarged in 
(b,d), respectively. me, head mesenchyme surrounding the optic vesicle. Scale bars: 50 μm in (a,c) and 20 μm in 
(b,d).
www.nature.com/scientificreports/
9Scientific RepoRts | 7: 53  | DOI:10.1038/s41598-017-00088-w
Generation of Pax6-CRISPR mice. Two sites encoding a portion of the PD (T1, T2) were selected as 
target sites (Fig. 1). Potential off-target sites in exonic regions were searched using CRISPR Design (http://crispr.
mit.edu)37 and listed as Table S8. Eye phenotypes we observed were not phenocopied by any knockouts of the 
candidate off-target genes listed. Production of Cas9 mRNA and T1 or T2 sgRNA, and RNA microinjection into 
mouse zygotes were performed as previously described9. Microinjection experiments were performed twice for 
each target site.
DNA sequencing of mutated endogenous gene target sites. Genomic DNA was isolated from 
the neck of fixed mouse embryos with a DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany). We used 
KOD-Plus-Neo (Toyobo, Osaka, Japan) or ExTaqHS (Takara, Kusatsu, Japan) and gene specific primers to isolate 
partial genomic DNA for Pax6_T1 and Pax6_T2 by PCR. The nucleotide sequences of the primers for Pax6_T1 
were 5′-GAA TCA GCT TGG TGT CTT T-3′ and 5′-GGT GGT GTA GTC AGT AAT TAG CGT-3′, and those for 
Pax6_T2 were 5′-CTC GTA CCA TTG AAG GTA TAT TTT TGT-3′ and 5′-TTA TAC TGG GCT ATT TTG CTT 
ACA ACT-3′. The sizes of the desired amplicons were 253 bp for Pax6_T1 and 301 bp for Pax6_T2. The purified 
PCR amplicons were subcloned as described9 or into pGEM-T-Easy plasmids (Promega, Fitchburg, WI). After 
transformation, plasmids were extracted from the resultant bacterial colonies or colony PCR was performed. 
Sequencing was performed in our laboratory with an ABI 3500xL Genetic Analyzer (Applied Biosystems, Foster 
City, CA) as described previously9 or by Eurofins Genomics (Tokyo, Japan). Mutated alleles were identified by 
comparison with the wild-type sequence in Genetyx-Mac software (Genetyx Co., Tokyo, Japan) and ClustalW 2.1 
accessed via the DNA Data Bank of Japan.
Histology and immunohistochemistry. Founder E16.5 and E11.5 embryos were obtained through 
Caesarian section and fixed in 4% paraformaldehyde in phosphate buffered saline overnight. After dehydra-
tion in serial ethanol series and clearing in xylene, the embryos were embedded in paraffin and cut into 
5-μm-thick sections for histology and 10-μm-thick sections for immunohistochemistry. After deparaffiniza-
tion, HE staining was performed according to standard procedures. Immunohistochemistry was performed by 
a Dextran polymer signal amplification system (EnVision HRP; Dako, Glostrup, Denmark). Anti-Pax6 (rabbit 
IgG, 1:1000 dilution; Covance, Princeton, NJ) and anti-βIII tubulin (Tuj1; mouse IgG, 1:500 dilution; Covance) 
primary antibodies were used for immunolabeling. The anti-Pax6 antibody was generated against the peptide 
(QVPGSEPDMSQYWPRLQ) derived from the C-terminus of the mouse Pax6 protein. Immunoreactivity was 
visualized by a peroxidase reaction with 3,3′-diaminobenzidine. Micrograph images were taken with a Nikon 
digital camera (DS-Ri1; Nikon, Tokyo, Japan) and processed in Adobe Photoshop CS 5.1 (Adobe Systems Inc., 
San Jose, CA). Histological sections from E11.5 embryos were partly immunostained using fluorescent secondary 
antibodies (Alexa Fluor 488 conjugate, anti-rabbit IgG; Thermo Fisher Scientific) and DAPI, and their images 
were taken with a Zeiss confocal laser-scanning microscope (LSM 780; Zeiss, Jena, Germany).
Morphometric analysis and statistics. The embryos containing all three classes were selected. In each 
embryo on each side, two serial (in principle) sections with the largest eye size were further selected and images of 
immunostained eyes were captured by a Nikon CCD camera. The area of Pax6-positive domains in the immunos-
tained retinal sections was measured using ImageJ (https://imagej.nih.gov/ij/index.html). Tuj1-immunostained 
area and retinal domains were also measured in the same way. Briefly, “unit of length” was set as μm and the 
images were changed to 8 bit. The weak but obviously stained portion in each image was marked using “freehand 
selections” and “enhance contrast” was processed under the following conditions: saturated pixels 5%, normalize, 
and update all when normalizing. Further, two types of filtering, “median” (radius 3.0 pixels, and 6.0 for larger 
magnification) and “unsharp mask” (sigma 3.0 or 6.0 pixels, mask weight 0.7) were processed. Threshold adjust-
ment was set as “Otsu”. The retinal domains to be measured were marked by “freehand selections” tool and the 
domains to be analyzed were selected, converted to black, and the areas (μm2) were measured. “The retina” here 
included neural retina, retinal pigmented epithelium, and optic nerve, and excluded lens, retinal vessels and 
blood cells. Statistical analysis of Chi-squared test and calculation of Spearman’s rank correlation coefficient was 
performed using IBM SPSS Statistics ver.24 (IBM Corporation, Armonk, NY).
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